Gilotrif Approval Gives Boehringer Milestone, But Can It Compete With Tarceva?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approval of its first oncology drug is a victory for Boehringer Ingelheim. Now comes another challenge – a commercial battle with Roche’s Tarceva, which is firmly established across lines of therapy for EGFR-positive lung cancer patients.